These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 11585445)

  • 21. Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.
    Huang PP; Randolph JT; Klein LL; Vasavanonda S; Dekhtyar T; Stoll VS; Kempf DJ
    Bioorg Med Chem Lett; 2004 Aug; 14(15):4075-8. PubMed ID: 15225729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of novel small non-peptidic HIV-1 PIs: the benzothiophene ring as an effective moiety.
    Chiummiento L; Funicello M; Lupattelli P; Tramutola F; Berti F; Marino-Merlo F
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2948-50. PubMed ID: 22414613
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Microwave-accelerated synthesis of P1'-extended HIV-1 protease inhibitors encompassing a tertiary alcohol in the transition-state mimicking scaffold.
    Ekegren JK; Ginman N; Johansson A; Wallberg H; Larhed M; Samuelsson B; Unge T; Hallberg A
    J Med Chem; 2006 Mar; 49(5):1828-32. PubMed ID: 16509598
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors.
    Adrian Meredith J; Wallberg H; Vrang L; Oscarson S; Parkes K; Hallberg A; Samuelsson B
    Eur J Med Chem; 2010 Jan; 45(1):160-70. PubMed ID: 19926360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rational design, synthesis, and crystallographic analysis of a hydroxyethylene-based HIV-1 protease inhibitor containing a heterocyclic P1'--P2' amide bond isostere.
    Thompson SK; Murthy KH; Zhao B; Winborne E; Green DW; Fisher SM; DesJarlais RL; Tomaszek TA; Meek TD; Gleason JG
    J Med Chem; 1994 Sep; 37(19):3100-7. PubMed ID: 7932533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity.
    Chen P; Cheng PT; Alam M; Beyer BD; Bisacchi GS; Dejneka T; Evans AJ; Greytok JA; Hermsmeier MA; Humphreys WG; Jacobs GA; Kocy O; Lin PF; Lis KA; Marella MA; Ryono DE; Sheaffer AK; Spergel SH; Sun CQ; Tino JA; Vite G; Colonno RJ; Zahler R; Barrish JC
    J Med Chem; 1996 May; 39(10):1991-2007. PubMed ID: 8642558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Pseudo-Symmetric
    D'Orsi R; Funicello M; Laurita T; Lupattelli P; Berti F; Chiummiento L
    Biomolecules; 2021 Oct; 11(11):. PubMed ID: 34827582
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stereospecific synthesis, structure-activity relationship, and oral bioavailability of tetrahydropyrimidin-2-one HIV protease inhibitors.
    De Lucca GV; Liang J; De Lucca I
    J Med Chem; 1999 Jan; 42(1):135-52. PubMed ID: 9888839
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Probing Lipophilic Adamantyl Group as the P1-Ligand for HIV-1 Protease Inhibitors: Design, Synthesis, Protein X-ray Structural Studies, and Biological Evaluation.
    Ghosh AK; Osswald HL; Glauninger K; Agniswamy J; Wang YF; Hayashi H; Aoki M; Weber IT; Mitsuya H
    J Med Chem; 2016 Jul; 59(14):6826-37. PubMed ID: 27389367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High-speed synthesis of potent C2-symmetric HIV-1 protease inhibitors by in-situ aminocarbonylations.
    Wannberg J; Kaiser NF; Vrang L; Samuelsson B; Larhed M; Hallberg A
    J Comb Chem; 2005; 7(4):611-7. PubMed ID: 16004505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P1/P1' modified HIV protease inhibitors as tools in two new sensitive surface plasmon resonance biosensor screening assays.
    Alterman M; Sjöbom H; Säfsten P; Markgren PO; Danielson UH; Hämäläinen M; Löfås S; Hultén J; Classon B; Samuelsson B; Hallberg A
    Eur J Pharm Sci; 2001 May; 13(2):203-12. PubMed ID: 11297905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
    Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
    J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis, antiviral activity and pharmacokinetics of P1/P1' substituted 3-aminoindazole cyclic urea HIV protease inhibitors.
    Kaltenbach RF; Patel M; Waltermire RE; Harris GD; Stone BR; Klabe RM; Garber S; Bacheler LT; Cordova BC; Logue K; Wright MR; Erickson-Viitanen S; Trainor GL
    Bioorg Med Chem Lett; 2003 Feb; 13(4):605-8. PubMed ID: 12639540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
    Dewdney TG; Wang Y; Liu Z; Sharma SK; Reiter SJ; Brunzelle JS; Kovari IA; Woster PM; Kovari LC
    Bioorg Med Chem; 2013 Dec; 21(23):7430-4. PubMed ID: 24128815
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expedient solid-phase synthesis of both symmetric and asymmetric diol libraries targeting aspartic proteases.
    Shi H; Liu K; Leong WW; Yao SQ
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3945-8. PubMed ID: 19328682
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and biological evaluation of HIV-1 protease inhibitors with morpholine derivatives as P2 ligands in combination with cyclopropyl as P1' ligand.
    Dou Y; Zhu M; Dong B; Wang JX; Zhang GN; Zhang F; Wang YC
    Bioorg Med Chem Lett; 2020 Apr; 30(7):127019. PubMed ID: 32057582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Symmetry-based inhibitors of HIV protease. Structure-activity studies of acylated 2,4-diamino-1,5-diphenyl-3-hydroxypentane and 2,5-diamino-1,6-diphenylhexane-3,4-diol.
    Kempf DJ; Codacovi L; Wang XC; Kohlbrenner WE; Wideburg NE; Saldivar A; Vasavanonda S; Marsh KC; Bryant P; Sham HL
    J Med Chem; 1993 Feb; 36(3):320-30. PubMed ID: 8426362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new class of HIV-1 protease inhibitors containing a tertiary alcohol in the transition-state mimicking scaffold.
    Ekegren JK; Unge T; Safa MZ; Wallberg H; Samuelsson B; Hallberg A
    J Med Chem; 2005 Dec; 48(25):8098-102. PubMed ID: 16335934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.
    Thompson WJ; Fitzgerald PM; Holloway MK; Emini EA; Darke PL; McKeever BM; Schleif WA; Quintero JC; Zugay JA; Tucker TJ
    J Med Chem; 1992 May; 35(10):1685-701. PubMed ID: 1588551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.